| 1 |
28499845 | Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. | 2017 Sep |
1 |
| 2 |
29297305 | Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. | 2017 Dec 28 |
1 |
| 3 |
26255732 | Anti-Hepatitis C Virus Activity of a Crude Extract from Longan (Dimocarpus longan Lour.) Leaves. | 2016 May 20 |
1 |
| 4 |
26679249 | HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. | 2016 Mar |
1 |
| 5 |
25556540 | Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. | 2015 Jul |
1 |
| 6 |
25712364 | Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir. | 2015 May |
1 |
| 7 |
25818622 | A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants. | 2015 Jul |
1 |
| 8 |
25961497 | Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. | 2015 Aug 21 |
1 |
| 9 |
26140082 | Predictive factors associated with hepatitis C antiviral therapy response. | 2015 Jun 28 |
1 |
| 10 |
24647743 | Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group. | 2014 Jun |
1 |
| 11 |
24782254 | Targets for antiviral therapy of hepatitis C. | 2014 Feb |
1 |
| 12 |
25052594 | Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. | 2014 Nov |
2 |
| 13 |
23152524 | Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. | 2013 Feb |
1 |
| 14 |
23411358 | A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. | 2013 |
1 |
| 15 |
23501442 | A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. | 2013 May 5 |
1 |
| 16 |
24100495 | In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. | 2013 Dec |
3 |
| 17 |
24282816 | Hepatitis C virus NS3 inhibitors: current and future perspectives. | 2013 |
1 |
| 18 |
22848441 | Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir. | 2012 |
1 |
| 19 |
23188750 | The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. | 2012 |
1 |
| 20 |
22195237 | The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. | 2011 Dec |
1 |
| 21 |
22440917 | Resistance to anti-HCV protease inhibitors. | 2011 Dec |
1 |
| 22 |
21473061 | [Inhibitors of hepatitis C virus--therapeutic possibilities]. | 2010 |
1 |